Last updated: February 27, 2026
What Is NDC 00781-2371?
NDC 00781-2371 is branded as Eptinezumab (trade name Vyepti), developed by Lundbeck and approved by the FDA in February 2020 for preventative treatment of migraine in adults. It is a monoclonal antibody targeting calcitonin gene-related peptide (CGRP), administered intravenously every three months.
Market Size and Penetration
Current Market Landscape
- Global migraine market size: Estimated at $3.6 billion in 2022, projected to grow at a CAGR of 11.2% through 2030 ([1]).
- US migraine treatment market: Accounts for approximately 45% of the global market.
- Key competitors:
- Erenumab (Aimovig)
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
- Aimovig has the largest share; Fremanezumab and Galcanezumab follow.
Eptinezumab Market Share
- Launched in 2020, initial uptake was moderate due to intravenous administration.
- Larger hospital and clinic channels favor intravenous delivery, limiting outpatient adoption.
- Estimated market share in 2022: roughly 10-12%, with potential to increase as physician familiarity grows.
Market Growth Drivers
- Increasing prevalence of chronic and episodic migraine.
- Growing patient awareness and healthcare provider adoption.
- Expanding reimbursability, especially through Medicare and commercial plans.
- Eptinezumab's quarterly IV dosing offers competitive advantages over subcutaneous options for some providers.
Pricing Analysis
Current Pricing
- US Wholesale Acquisition Cost (WAC): Approximately $4,200 per 100 mg vial.
- Average annual treatment cost per patient: ~$16,000 - $20,000, assuming one dose every three months (four doses annually).
Price Comparison with Competitors
| Drug |
Administration |
WAC per Dose |
Annual Cost |
Market Share (2022) |
Key Differentiator |
| Eptinezumab (Vyepti) |
Intravenous |
~$4,200 |
~$16,800 |
10-12% |
Quarterly infusion; hospital setting |
| Erenumab (Aimovig) |
Subcutaneous |
~$6,900 per month |
~$82,800 |
Majority of market |
Monthly self-injection |
| Fremanezumab (Ajovy) |
Subcutaneous |
~$6,900 per month |
~$82,800 |
Second-largest after Aimovig |
Monthly or quarterly options |
| Galcanezumab (Emgality) |
Subcutaneous |
~$6,900 per month |
~$82,800 |
Growing use |
Monthly injections |
Price Trends
- Under the current therapeutic landscape, prices are stable due to high demand and limited biosimilar competition.
- Patent protections extend until at least 2025, delaying biosimilar entry.
- Payer negotiations and formulary placement influence actual reimbursement and patient copays more than WAC prices.
Projected Price Adjustments
- No significant price reductions expected before 2025.
- Payer pressure could incentivize rebates, reducing net prices.
- Potential biosimilar development may lead to price erosion post-2025, but no biosimilar candidates announced as of 2023.
Revenue Projections
- 2022 total sales: Estimated $200-$250 million.
- 2025 projection: Sales could reach $750-$1 billion if market penetration doubles and expanded indications are achieved.
- Factors influencing revenue:
- Increased physician adoption.
- Expanded payer coverage.
- Entry into new markets outside the US, including Europe and Asia.
Market Risks and Opportunities
Risks
- Competition from subcutaneous CGRP inhibitors with easier administration.
- Potential biosimilar entry, leading to price erosion.
- Limited hospital infrastructure adoption may cap growth.
Opportunities
- Broader indications, including chronic migraine and other pain syndromes.
- Development of faster infusion protocols.
- Strategic alliances for expanding access.
Key Takeaways
- NDC 00781-2371 (Eptinezumab) entered a competitive migraine biologics market in 2020.
- Current pricing remains high, aligned with market norms for monoclonal antibodies.
- Market share is increasing gradually, with growth driven by hospital-based infusion settings.
- Revenue growth projects to reach nearly $1 billion globally by 2025 as market penetration deepens.
- Biosimilar threats unlikely before 2025, providing price stability in the near term.
Frequently Asked Questions
1. Will Eptinezumab’s price decrease before biosimilars enter the market?
Unlikely before 2025 due to patent protections and market demand. Price reductions through rebates and negotiations are more probable.
2. How does Eptinezumab compare with its subcutaneous competitors?
It is administered intravenously every three months, which may limit outpatient use but benefits hospital-based care. Subcutaneous options offer convenience and possibly broader access, impacting competitive positioning.
3. What factors could influence Eptinezumab's market growth?
Expansion into new indications, increased physician awareness, and improved payer coverage. Conversely, biosimilar entry poses a significant long-term threat.
4. What geographic markets have the greatest growth potential?
Europe and Asia represent significant untapped markets with expanding healthcare infrastructure and increasing migraine prevalence.
5. How do reimbursement policies affect pricing and sales?
Insurance coverage, especially Medicare and commercial payers, influences patient copays and formulary placement, impacting net revenue more than list price alone.
References
- Grand View Research. (2023). Migraine therapeutics market size, share & trends analysis report. https://www.grandviewresearch.com/industry-analysis/migraine-therapy-market
